Poor
Not Aligned
Patient Risk:
Low
Summary
Most claims (ANDA submission/approval, FDA review timeline, and generic approval specifics) are not supported by the provided FDA label extract. Mechanism-of-action/JAK pathway claims are supported, but key indication/safety-related claims cannot be verified from the supplied label text.
Category Scores
Accurate Statements
Ruxolitinib is a Janus kinase (JAK) inhibitor.
Supported by 12.1 Mechanism of Action: “inhibits Janus Associated Kinases (JAKs), JAK1 and JAK2”.
Ruxolitinib targets the JAK pathway.
Supported by 12.1: JAK inhibition and downstream JAK-STAT signaling modulation.
Unsupported Statements
Apotex submitted an Abbreviated New Drug Application (ANDA) for ruxolitinib to the FDA in 2014.
No ANDA/submission history is provided in the available label sections.
Apotex submitted its ruxolitinib ANDA to the FDA on October 15, 2014.
No ANDA submission date information is provided in the available label sections.
The FDA completed its review of Apotex's ruxolitinib ANDA in 2015 and determined that the generic version met necessary standards.
No FDA review timeline or determinations about a specific applicant are provided in the available label sections.
Apotex received FDA approval for its ruxolitinib ANDA in 2016.
No generic approval history is provided in the available label sections.
Ruxolitinib is approved by the FDA for the treatment of myelofibrosis.
The provided extract contains only a placeholder for section 1 (Indications and Usage) and does not include indication text.
Ruxolitinib is approved by the FDA for the treatment of polycythemia vera.
The provided extract contains only a placeholder for section 1 (Indications and Usage) and does not include indication text.
Ruxolitinib alleviates symptoms associated with myeloproliferative neoplasms (MPNs).
No symptom-alleviation/clinical benefit statements are provided in the available label extract; 12.1 provided only mechanism information.
Contradictions
Important Omissions
Section 1 Indications and Usage content (specific labeled indications, dosing context) is not present in the provided extract, preventing verification of the indication claims against label text.
Importance:
Moderate
No FDA label content for boxed warnings, contraindications, dosing/administration, monitoring, adverse reactions, drug interactions, or use in specific populations is included in the provided extract, limiting evaluation of safety-relevant alignment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are primarily about ANDA submission/approval history and symptom/indication statements; the only directly supported pharmacologic mechanism claims are not unsafe by themselves. However, missing label sections prevent verification of safety-related labeling elements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple substantive claims (ANDA submission/approval timeline, generic approval details, and MPN symptom alleviation; and approval indications) are not supported by the provided FDA label extract.
Suggested Improvement
Restrict assertions to what is present in the provided label text (e.g., mechanism/JAK inhibition from 12.1). Do not include ANDA submission/approval timeline details or indication/clinical benefit statements unless section 1 and relevant clinical sections are provided for verification.